A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake

Clinical Cancer Research

Volumn 11, Issue 13, 2005, Pages 4810-4817

  Scott, Andrew M ^a,b   Lee, Fook Thean ^a   Jones, Robert ^b   Hopkins, Wendie ^a   MacGregor, Duncan ^b   Cebon, Jonathan S ^a   Hannah, Anthony ^a,b   Chong, Geoffrey ^a   U, Paul ^b   Papenfuss, Anthony ^b   Rigopoulos, Angela ^a   Sturrock, Susan ^b   Murphy, Roger ^a   Wirth, Veronika ^a   Murone, Carmel ^a,b   Smyth, Fiona E ^a   Knight, Simon ^b   Welt, Sydney ^a   Ritter, Gerd ^a   Richards, Elizabeth ^a   Nice, Edouard C ^a   Burgess, Antony W ^a   Old, Lloyd J ^a   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

A33 ANTIGEN; ANTIGEN; HUMANIZED MONOCLONAL ANTIBODY A33; HUMANIZED MONOCLONAL ANTIBODY A33 I 125; HUMANIZED MONOCLONAL ANTIBODY A33 I 131; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BIOSENSOR; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TARGETING; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IN VIVO STUDY; ISOTOPE LABELING; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIDE EFFECT; TUMOR BIOPSY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 27144522470     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2329     Document Type: Article

References (41)

1. Trichopoulos D, Petridou E, Lipworth L, Adami HO. Epidemiology of cancer. In: Rosenberg SA. Cancer: principles and practise of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 235-48.
2. Weisburger JH. Causes, relevant mechanisms, and prevention of large bowel cancer. Semin Oncol 1991;18:316-36.
3. Lynch HT, Smyrk T, Watson P, et al. Hereditary colorectal cancer. Semin Oncol 1991;18:337-66.
4. Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7:1419-26.
5. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447-56.
6. Mohiuddin M, Marks G. Adjuvant radiation therapy for colon and rectal cancer. Semin Oncol 1991;18:411-20.
7. Scott AM, Cebon J. Clinical promise of tumour immunology. Lancet 1997;349:SII19-22.
8. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
9. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
10. Catimel B, Ritter G, Welt S, et al. Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium. J Biol Chem 1996;271:25664-70.
11. Heath JK, White SJ, Johnstone CN, et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 1997;94:469-74.
12. Ritter G, Cohen LS, Nice EC, et al. Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. Biochem Biophys Res Commun 1997;236:682-6.
13. Garin-Chesa P, Sakamoto J, Welt S, Real FX, Rettig WJ, Lloyd JO. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol 1996;9:465-71.
14. Van den Eynde BJ, Scott AM. Tumor Antigens. In: Roitt IM, editor. Encyclopedia of immunology. 2nd ed. Vol. 4. London: Academic Press; 1998. p. 2424-31.
15. Welt S, Divgi CR, Real FX, et al. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol 1990;8:1894-906.
16. Welt S, Divgi CR, Kemeny N, et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994;12:1561-71.
17. Welt S, Scott AM, Divgi CR, et al. Radio-immunotherapy of colon cancer with monoclonal antibody A33. Tumor Targeting 1995;1:299-300.
18. Welt S, Scott AM, Divgi CR, et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996;14:1787-97.
19. Scott AM, Welt S. Antibody-based immunological therapies. Curr Opin Immunol 1997;9:717-22.
20. 131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 1997;57:2181-6.
21. King DJ, Antoniw P, Owens RJ, et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer 1995;72:1364-72.
22. Welt S, Ritter G, Williams C Jr, et al. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2003;9:1347-53.
23. Welt S, Ritter G, Williams C Jr, et al. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 2003;9:1338-46.
24. Barendswaard EC, Scott AM, Divgi CR, et al. Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. Int J Oncol 1998;12:45-53.
25. 124I-CDR-grafted humanized A33 monoclonal antibody. J Nucl Med 2001;42:764-9.
26. Scott AM, Geleick D, Rubira M, et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res 2000;60:3254-61.
27. Ritter G, Cohen LS, Williams C Jr, Richards EC, Old LJ, Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001;61:6851-9.
28. Lipkin M, Sherlock P, Bell B. Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum. Gastroenterology 1963;45:721-9.
29. Ajani JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. Cancer J 2000;6:78-81.
30. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406-14.
31. Scott AM, Wiseman G, Welt S, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003;9:1639-47.
32. Posey JA, Ng TC, Yang B, et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003;9:1323-32.
33. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
34. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
35. Caron PC, Jurcic JG, Scott AM, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994;83:1760-8.
36. van Hof AC, Molthoff CF, Davies Q, et al. Biodistribution of (111)indium-labeled engineered human antibody CTM01 in ovarian cancer patients: influence of protein dose. Cancer Res 1996;56:5179-85.
37. Scott AM, Lee FT, Hopkins W, et al. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J Clin Oncol 2001;19:3976-87.
38. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
39. 131I] anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-65.
40. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995;346:336-40.
41. Clark M. Antibody humanization: a case of the "Emperor's new clothes"? Immunol Today 2000;21:397-402.